Concentric Medical Announces First Stroke Patients Treated With the Merci Retriever(R) in Japan

MOUNTAIN VIEW, California, July 21, 2010 - Concentric Medical, Inc., the global leader in devices for clot removal
in acute ischemic stroke patients, today announced the treatment of the first
patient in Japan with the Merci Retriever(R). The Merci Retriever is a
catheter-based medical device that stroke centers use to remove blood clots
from the brains of patients suffering an acute ischemic stroke.

Nobuyuki Sakai, M.D., D.M.Sc., Director, Neurosurgery & Stroke Center at
Kobe City General Hospital said, "The Merci Retriever, which recently
received Shonin approval in Japan, was used in its first case at Kobe City
General Hospital. We have been looking forward to the introduction of this
device and we were very excited to have the first successful treatment of a
cerebral artery occlusion in Japan. I am confident that the neurosurgeons and
neurologists at acute stroke centers will be using the Merci Retriever very
shortly and enrolling patients in the post-market study. The post-market
study for the Merci Retriever will further validate the safety and efficacy
in this new era of cerebral artery revascularization therapy."

Wade S. Smith, M.D., Ph.D., Professor of Neurology & Director, University
of California, San Francisco Neurovascular Service and principal investigator
of both the Merci and Multi Merci clinical trials said, "I am very happy to
hear that the first patient in Japan has benefited from mechanical
thrombectomy with the Merci Retriever. It is my expectation that Japanese
endovascular neurosurgeons and neurologists will rapidly change the status of
stroke care in Japan using this stroke therapy, much like what has happened
in the United States."

On May 4th, Concentric Medical announced the Shonin approval of the Merci
Retriever(R), Merci(R) Microcatheter, and Merci(R) Balloon Guide Catheter.
Century Medical Inc. of Japan is Concentric Medical's exclusive distribution
partner. The two companies worked together to obtain Shonin approval for the
Merci Retriever, which is the first device for clot removal for ischemic
stroke patients to be approved in Japan.

Maria Sainz, President and CEO of Concentric Medical said, "I am thrilled
that the first patient has been successfully treated with the Merci Retriever
in Japan. This first patient in Japan is a significant milestone for all
those involved in making the Merci Retriever available to acute ischemic
stroke patients throughout the world. We look forward to working closely with
Japanese physicians and our distribution partner, Century Medical, to drive
the successful adoption of Merci. The approval and clinical use of the Merci
Retriever in Japan is another example of how we continue to build on our
strong heritage in the treatment of acute ischemic stroke."

Akira Hoshino, President and CEO of Century Medical said, "The initial
patient treated with the Merci Retriever in Japan is very rewarding for
everyone involved in the advancement of interventional stroke care in Japan.
This initial case is an exciting example of how the Merci Retriever provides
a unique treatment option for physicians and stroke patients in Japan.
Century Medical is strongly committed to working with physicians and
hospitals throughout Japan to make the Merci Retriever widely available for
Japanese stroke patients."

About Concentric Medical

Concentric Medical is located in Mountain View, California, and is the
global leader in the development of endovascular devices for revascularizing
stroke patients. The company manufactures and markets solutions for ischemic
stroke: minimally invasive devices that are delivered into the brain to
restore blood flow by removing blood clots that cause ischemic stroke.
Concentric Medical's devices are available in over 500 leading stroke centers
around the world, and have been the subject of several clinical studies. For
more information about Concentric Medical, please visit
www.concentric-medical.com.

About Acute Ischemic Stroke

Stroke is the third leading cause of death in the developed world and the
leading cause of serious long-term disability. Ischemic stroke represents
over 85% of strokes and occurs when a blockage or clot develops in one of the
arteries supplying blood to the brain. In 2004 the FDA cleared Concentric
Medical's Merci Retriever(R) for use in stroke patients who are ineligible
for IV-tPA or who fail to respond to IV-tPA therapy. This pioneering device
created a departure from the historic method of caring for stroke patients
and offered physicians and patients a long-awaited option for stroke
intervention.

For more information about Concentric Medical, please visit
www.concentric-medical.com.

    Media Contact:
    +1-650-938-2100
    strokeinfo@concentric-medical.com

Concentric Medical, +1-650-938-2100, strokeinfo at concentric-medical.com